Navigation Links
Biotest Pharmaceuticals Corporation Responds to Orphan Drug Act Announcement
Date:3/27/2008

BOCA RATON, Fla., March 27 /PRNewswire/ -- Biotest Pharmaceuticals Corporation, a leading developer of immunology biotherapeutic products, today responded to an announcement that a Hepatitis B Immune Globulin Intravenous (Human) product manufactured by another company has received Orphan Drug designation by the U.S. Food and Drug Administration (FDA) for the prevention of hepatitis B recurrence following orthotopic liver transplantation.

"The designation announced yesterday does not affect our ability to continue to provide Nabi-HB(R) to the marketplace. Nabi-HB has been the industry gold standard for the prevention of hepatitis B infection following accidental exposure to hepatitis B virus and many hospitals, physicians and patients have come to rely on Nabi-HB's long, safe and effective history since its approval in the late 1990s. We are committed to continuing to work with our partners and the medical and patient community to provide Nabi-HB to those who need it. Biotest Pharmaceuticals also is committed to continuing our research and development activities in the hepatitis liver transplant community," said Dr. Rainer Pabst, Chief Executive Officer of Biotest Pharmaceuticals.

Biotest Pharmaceuticals acquired Nabi-HB as part of the company's acquisition of Nabi Biopharmaceuticals' Biologics Strategic Business Unit in December 2007.

About Biotest Pharmaceuticals Corporation

Biotest Pharmaceuticals Corporation develops and manufactures pharmaceutical and biotherapeutic products with a specialization in immunology. Biotest Pharmaceuticals will offer the hyperimmunoglobulin Nabi- HB(R), a key product used in the prevention of hepatitis B. Biotest Pharmaceuticals also is currently working to develop additional products including a polyvalent immunoglobulin (IVIG, Phase III) and Civacir(R) (Phase IIb), for the prevention of hepatitis C in liver transplant patients. Biotest Pharmaceuticals was formed in 2007 as part of the Biotest AG acquisition of Nabi Biopharmaceuticals' Biologics business unit, including its plasmapheresis centers across the United States. The company employs approximately 500 people in the U.S. Biotest Pharmaceuticals is a subsidiary of Biotest AG, a German- based global provider of plasma proteins that employs approximately 1,750 people worldwide.


'/>"/>
SOURCE Biotest Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
2. AUDIO from Medialink and Solvay Pharmaceuticals: Men with Type 2 Diabetes at Increased Risk for Low Testosterone Should Talk to Their Doctors
3. MAP Pharmaceuticals Appoints H. Ward Wolff to Board of Directors
4. Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., as Chief Medical Officer
5. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
6. Dreier LLP Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated (VRTX)
7. Alseres Pharmaceuticals, Inc. Raises $5 Million
8. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
9. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
10. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated
11. Sagent Pharmaceuticals Launches Ciprofloxacin Injection, USP, 5% Dextrose Premix Bag
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... California (PRWEB) , ... January 23, 2017 , ... Old ... principles, has added Mr. Olympia Classic Physique bodybuilder Breon Ansley to its growing team ... competing as a bodybuilder in 2012 and in less than a year was able ...
(Date:1/23/2017)... , ... January 23, 2017 , ... ... high-quality general gynecological care and gynecological services for women of all ... care for a wide variety of reproductive services from routine health screenings to ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Crossing the Bar”: ... minutes of a woman’s life. “Crossing the Bar” is the creation of published author, ... children. , Charlotte, who credits the inspiration of the book to her sister, ...
(Date:1/23/2017)... ... ... “Life Under Blankets”: an entrancing story about one woman's travels through ... the creation of published author, Kimberly Mitchell, who earned her bachelor’s degree in English ... pursue a master’s degree in education in the field of curriculum and instruction. Kimberly’s ...
(Date:1/23/2017)... ... January 23, 2017 , ... Valentine’s Day is a time when many people celebrate romance ... those who may be looking for the ideal present, Atlanta-based Perimeter Plastic Surgery ... additional $25 free. Or, spend $200 and get $50 free. , “A lot of ...
Breaking Medicine News(10 mins):
(Date:1/22/2017)... Saudi Arabia , January 22, 2017 ... US and UAE discuss the ... at the World Economic Forum   "The management and delivery of ... and powered by artificial intelligence and this trend is going to get bigger ... the Future, at the concluding day of the 47 th Annual Meeting ...
(Date:1/21/2017)... 2017 According to a new market research ... R&D, Compliance, SCM), Component (Software, Service), Delivery (On premise, Cloud), End ... by MarketsandMarkets, the market is expected to reach USD 24.73 Billion ... of 13.3% during the forecast period. ... ...
(Date:1/21/2017)... Research and Markets has announced the addition of the ... Administration, End User - Forecast to 2025" report to their ... The Global ... of around 7.8% over the next decade to reach approximately $330.70 ... global markets for Advanced Drug Delivery across all the given segments ...
Breaking Medicine Technology: